Elke Neumann-Haefelin

Current Position

Senior Attending Physician

Academic Education

2009	Visiting Scientist, Joslin Diabetes Center, Harvard Medical School, Boston, USA
2007 - present	Independent Research Group Leader, Nephrology, Medical Center - University of Freiburg
2005 - 2006	Postdoctoral Fellow, Institute of Bioinformatics & Molecular Genetics, Faculty of Biology, University of Freiburg
2003 - 2004	Residency in Medicine, Medical Center - University of Freiburg
1998 - 2001	MD thesis, Functional dissection of Trigger Factor and Dank: Interactions with nascent polypeptides (summa cum laude), Institute for Biochemistry and Molecular Biology, Medical Center - University of Freiburg
1996 - 2003	Medical School, University of Freiburg

Advanced Qualifications

2021	Professor (apl) Internal Medicine
2015	Habilitation in Internal Medicine, University of Freiburg
2013	Board Certification (Facharztprüfung) in Nephrology
2011	Board Certification (Facharztprüfung) in Internal Medicine
2003	German Medical Licence (Approbation)
2003	MD in Physiology, University of Freiburg

Postgraduate Positions

Since 2019	Head of von Hippel-Lindau Division
2019 - 2020	Berta Ottenstein Grant for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg
Since 2016	Board member Vasculitis Center; Medical Center - University of Freiburg
2012 - 2019	Margarete von Wrangell Stipendary (Ministerium für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg)
2011 - present	Senior Attending Physician, Renal Division, Medical Center - University of Freiburg
2007 - 2011	Residency Internal Medicine, Medical Center - University of Freiburg
2005 - 2006	Postdoctoral Fellow, Intitute of Bioinformatics & Molecular Genetics, Faculty of Biology, University of Freiburg
2003 - 2004	Residency Internal Medicine, Medical Center - University of Freiburg

Link to all publications of Elke Neumann-Haefelin: PubMed

Publications on CRC 1453 funding

Pilz JF, Klein M, Neumann-Haefelin E, Ganner A. VHL-dependence of EHHADH Expression in a Human Renal Cell Carcinoma Cell Line. J Kidney Cancer VHL (2024). Jaki L, Weigang S, Kern L, Kramme S, Wrobel AG, …, Neumann-Haefelin E, Schnepf D, Welte T, Kochs G, Huzly D, Panning M, Fuchs J. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient. Nat Commun (2023). Mohl DA, Lagies S, Zodel K, Zumkeller M, Peighambari A, Ganner A, Plattner DA, Neumann-Haefelin E, Adlesic M, Frew IJ, Kammerer B. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells (2023). Ganner A, Philipp A, Lagies S, Wingendorf L, Wang L, Pilz F, Welte T, …, Frew IJ, Walz G, Neumann-Haefelin E. SCD5 Regulation by VHL Affects Cell Proliferation and Lipid Homeostasis in ccRCC. Cells (2023). Welte T, Arnold F, Westermann L, Rottmann FA, Hug MJ, Neumann-Haefelin E, Ganner A. Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study. BMC Nephrol (2023). Ganner A, Gehrke C, Klein M, Thegtmeier L, Matulenski T, …, Walz G, Frew IJ, Neumann-Haefelin E. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci Rep (2021).